Trial Profile
Antibody persistence in Australian adolescents following meningococcal C conjugate vaccination.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Dec 2015
Price :
$35
*
At a glance
- Drugs Meningococcal vaccine group C conjugate (Primary)
- Indications Meningococcal group C infections
- Focus Therapeutic Use
- Sponsors Novartis
- 07 Dec 2015 New trial record